There are certain select sectors that have the tendency of bringing stock market winners at a remarkable rate. Biotech stocks are certainly on that list. The companies in the biotech sector have consistently come up with impressive products and the advancements made in the sector are expected to lead to further growth.
However, if one has to choose stocks to invest in, then he would need to put in the necessary research. The best way of going about it is by watching the market closely. Here is a look at 3 biotech stocks that should be tracked by investors.
PharmaCyte Biotech (PMCB)
PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”
For more on PharmaCyte, Click Here
Oncolytics Biotech (ONCY)
The first biotech stock to consider is that of Oncolytics Biotech, Inc. (NASDAQ:ONCY). The stock has been on a highly impressive run since it made a major announcement on October 22.
The company is currently in the process of developing an immuno-oncolytic virus named pelareorep but last Tuesday it announced that it is going to collaborate with cancer research outfit PrECOG LLC for the same.
PrECOG is a particularly well-known name in this particular space and hence, the collaboration has been given the thumbs up by investors. It gives the company a bigger chance to get the product ready. The stock has climbed by as much as 60% over the past two weeks.
IVERIC bio (ISEE)
The other biotech stock which has been on fire this morning is that of IVERIC bio Inc (NASDAQ:ISEE). The company which is involved in manufacturing products for eye care announced highly positive data with regards to its product Zimura.
The medicine is a C5 inhibitor and it managed to reach the primary endpoint in this particular clinical study. Phase 2 studies also revealed that geographic atrophy (GA) had been reduced by 27.38% over the course of a year in the patients who had been tested.
The micro-cap biotech stock rose by as much as 83% after the announcement was made and should be tracked closely by investors over the coming days.
REPORT | ONE BIOTECH STOCK IS POSITIONING ITSELF FOR SUCCESS
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.
